Lung cancer and cellular aging markers — prospective cohort
Official title: Identification of Aging Biomarkers for Better Tailoring of Cancer Treatment in Older Patients With Lung Cancer: a Multicenter Clinico-biological Cohort Study
Run by Assistance Publique - Hôpitaux de Paris · NCT06923618 · Data updated 2026-11-12
We will test whether aging and senescence markers measured in blood and tissue can help predict outcomes for people aged 70 and older who are having curative surgery for early to locally advanced non-small cell lung cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 70 Years and up |
| Sex | All |
| Enrollment | 385 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Créteil, Île-de-France Region) |
| Status | Recruiting |
| Started | July 9, 2025 |
| Main results expected | July 2028 |
| Study ends | July 2032 |
| Registry record updated | December 15, 2025 |
| Trial ID | NCT06923618 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People aged 70 or older with clinically or histologically suspected stage I–IIIA non‑small cell lung cancer who are scheduled for curative-intent surgery and can give informed consent.
✕Probably not a fit
Patients younger than 70, those with metastatic disease or synchronous non‑lung cancers within six months, or patients unable to consent are unlikely to benefit from the study's results.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective cohort enrolls patients aged 70 and older with clinical or histologic stage I–IIIA non‑small cell lung cancer scheduled for curative-intent surgery. Blood samples and surgical tissue will be collected to measure methylome-based epigenetic age, telomere integrity, inflammaging markers, and senescent cells. Biomarker data will be combined with geriatric assessments and clinical follow-up to link markers with outcomes such as early death, major complications, unplanned hospitalization, treatment toxicity, and quality of life. The study aims to determine whether these quantitative aging measures improve prognostic stratification and support surgical decision-making for older patients.
Why it matters
Potential benefit: If successful, these markers could help doctors identify older patients at high risk of complications or early death so they can tailor treatment, monitoring, and supportive care.
How similar studies have gone: Related research on epigenetic clocks, telomere measures, and inflammaging has shown promising links to aging and adverse outcomes, but these biomarkers are not yet established for routine clinical prognosis in surgical lung cancer patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 70 years and over * Local or locally advanced (Clinic stage I-IIIA) NSCLC (clinically (or radiologically) suspected or histologically proven) * Surgical Curative Intent * Signed informed Consent (or signed by the curator or tutorship) * Affiliated to social security administrative care service Exclusion Criteria: * Synchronous cancer (histologically proven or strongly suspected non-lung cancer in the 6 months prior to inclusion (excluding basal cell cancer and prostate cancer with local treatment (radiotherapy or surgery) or active surveillance without systemic treatment (chemotherapy, hormone therapy)). * Subject deprived of liberty by judicial or administrative decision or patient under guardianship * Subject unable to understand the purpose and conditions of the study and unable to give consent
Where it's running
-
Henri Mondor Hospital
Créteil, Île-de-France Region, France Recruiting
Study contacts
- Principal investigator: Florence CANOUÏ-POITRINE, PhD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Florence CANOUÏ-POITRINE, PhD
- Email: florence.canoui-poitrine@aphp.fr
- Phone: 01 49 81 36 74
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
-
HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC
This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.